P/E của cổ phiếu MIRM là bao nhiêu?

Mirum Pharmaceuticals Inc (MIRM) hiện giao dịch ở mức P/E 2,224.08 lần.

ROE của cổ phiếu MIRM là bao nhiêu?

Mirum Pharmaceuticals Inc có tỷ suất lợi nhuận trên vốn chủ sở hữu (ROE) -329.43%.

Tỷ suất cổ tức của MIRM là bao nhiêu?

Mirum Pharmaceuticals Inc có tỷ suất cổ tức 0.00%.

Điểm chất lượng (Quality Score) của MIRM là bao nhiêu?

AI của chúng tôi đánh giá chất lượng tài chính tổng thể của MIRM ở mức 46/100, dựa trên khả năng sinh lời, tăng trưởng, nợ và độ ổn định lợi nhuận.

Bây giờ có nên mua cổ phiếu MIRM không?

Điểm AI Timing của MIRM là 56/100, thể hiện mức độ hấp dẫn tương đối của giá hiện tại theo tín hiệu kỹ thuật và momentum — nên cân nhắc cùng điểm chất lượng và kế hoạch đầu tư của bạn.

Cổ phiếu MIRM thuộc ngành nào?

Mirum Pharmaceuticals Inc được xếp vào ngành Healthcare >> Biotechnology trên sàn NASDAQ

Cổ phiếu MIRM (NASDAQ) | MIRUM PHARMACEUTICALS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-03 | FS: 2026-03-31)

MIRM AI Analysis Summary

Our AI summary for MIRM: Mirum Pharmaceuticals Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 2,224.08, ROE of -329.43%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 56/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

MIRM

Mirum Pharmaceuticals Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 96

USD 104.59

-1.36 (-1.28%) Day Change

Watchlist Portfolio Compare Chart

2,224.08

P/E

1.29

D/E

-329.4%

ROE

-89.7%

ROA

0.00%

Div Yield

-51.95

PEG

MIRUM PHARMACEUTICALS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 104.59 Price -1.36 (-1.28%) Day Change	NEWS SCORE: 96

MIRM Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 46) và Thời điểm mua ...(Sign In to See)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: Tỷ lệ P/E tương đối cao
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
Lịch sử ROE tương đối thấp
ROE đang giảm đáng kể
Tăng trưởng ROA hiện tại đang dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Lịch sử Biên lợi nhuận ròng tương đối thấp.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Khá , ...

Yếu tố Chất lượng

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	96
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	104.59
PBV / Sector	26.64 / 44,219.29
Earning Per Share	-12.93

PE / Sector	2,224.08 / 19.28
PEG or PE/Growth / Sector	-51.95 / 1.23
Average 1M Daily Value	67.95 M
Average 1W Daily Value	58.38 M

Yếu tố Kỹ thuật

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

43%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

60%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-140.24 / 98.22
NPM Average (%) / Sector	-86.91 / -1,697.63
NPM Change Average (%) / Sector	706.52 / 5,097.97 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-89.67 / 185,260.96
ROA Average (%) / Sector	-33.85 / 36,684.70
ROA Change Average (%) / Sector	743.35 / 422,221.66 GREAT
ROE (%) / Sector	-329.43 / 243,762.23
ROE Average (%) / Sector	-107.41 / 48,758.47
ROE Change Average (%) / Sector	1,046.10 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.19

Chi tiết đăng ký

Analyze Date	2026-08-04 08:01:51
Symbol	MIRM
Name	MIRUM PHARMACEUTICALS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	60.98 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	6,460.96 / 9,645.64

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 989 East Hillsdale Boulevard, Foster City, CA, United States, 94404

Phone: 650 667 4085

Website: https://www.mirumpharma.com

Employees: 418

Sector: Healthcare >> Biotechnology

Description: Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.